ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Integrated analysis of single-cell and Bulk RNA sequencing reveals a malignancy-related signature in lung adenocarcinoma

Wu, Mengxi; Wu, Zhenyu; Yan, Jun; Zeng, Jie; Kuang, Jun; Zhong, Chenghua; Zhu, Xiaojia; Mo, Yijun; Guo, Quanwei; Li, Dongfang; Tan, Jianfeng; Zhang, Tao; Zhang, Jianhua*佛山市第一人民医院; 南方医科大学; 1
Frontiers in Oncology2023-6-23DOI: 10.3389/fonc.2023.1198746
1被引8阅读
引用收藏
分享

摘要

BackgroundLung adenocarcinoma (LUAD), the most common histotype of lung cancer, may have variable prognosis due to molecular variations. The research strived to establish a prognostic model based on malignancy-related risk score (MRRS) in LUAD. MethodsWe applied the single-cell RNA sequencing (scRNA-seq) data from Tumor Immune Single Cell Hub database to recognize malignancy-related geneset. Meanwhile, we extracted RNA-seq data from The Cancer Genome Atlas database. The GSE68465 and GSE72094 datasets from the Gene Expression Omnibus database were downloaded to validate the prognostic signature. Random survival forest analysis screened MRRS with prognostic significance. Multivariate Cox analysis was leveraged to establish the MRRS. Furthermore, the biological functions, gene mutations, and immune landscape were investigated to uncover the underlying mechanisms of the malignancy-related signature. In addition, we used qRT-PCR to explore the expression profile of MRRS-constructed genes in LUAD cells. ResultsThe scRNA-seq analysis revealed the markers genes of malignant celltype. The MRRS composed of 7 malignancy-related genes was constructed for each patient, which was shown to be an independent prognostic factor. The results of the GSE68465 and GSE72094 datasets validated MRRS's prognostic value. Further analysis demonstrated that MRRS was involved in oncogenic pathways, genetic mutations, and immune functions. Moreover, the results of qRT-PCR were consistent with bioinformatics analysis. ConclusionOur research recognized a novel malignancy-related signature for predicting the prognosis of LUAD patients and highlighted a promising prognostic and treatment marker for LUAD patients.

学科与关键词

关键词
lung adenocarcinomaScRNA-seqmalignancygene signatureprognosis
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2023-06-23
卷期
第 13 卷
页码
1198746
DOI
10.3389/fonc.2023.1198746
成果收录
SCIE

作者

  • W

    Wu, Mengxi (第一作者)

    southern med univ

  • W

    Wu, Zhenyu

    first peoples hosp foshan

查看全部 13 位作者收起作者
  • Y

    Yan, Jun

    southern med univ

  • Z

    Zeng, Jie

    1

  • K

    Kuang, Jun

    southern med univ

  • Z

    Zhong, Chenghua

    southern med univ

  • Z

    Zhu, Xiaojia

    southern med univ

  • M

    Mo, Yijun

    southern med univ

  • G

    Guo, Quanwei

    southern med univ

  • L

    Li, Dongfang

    southern med univ

  • T

    Tan, Jianfeng

    southern med univ

  • Z

    Zhang, Tao

    southern med univ

  • Z

    Zhang, Jianhua (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417